Dr. Reddy's Drops Patent Challenge To Glaxo's Zofran

Law360, New York (April 29, 2004, 12:00 AM EDT) -- Indian generic drug maker Dr. Reddy's Laboratories has withdrawn its challenge to the main U.S. patent on GlaxoSmithKline anti-nausea drug Zofran, the U.K. drug maker said on Thursday.

As a result, Dr. Reddy's will not attempt to launch a cheap generic version of the product in the U.S. until after the compound patent expires in July 2005.

Glaxo also has two "method-of-use" patents expiring in 2005 and 2006.

GlaxoSmithKline had filed a lawsuit against Dr Reddy's Laboratories Ltd in the U.S.District Court for the district of...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.